KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) EBT Margin (2016 - 2025)

Historic EBT Margin for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to 30.17%.

  • Supernus Pharmaceuticals' EBT Margin fell 557500.0% to 30.17% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.04%, marking a year-over-year decrease of 141600.0%. This contributed to the annual value of 14.79% for FY2024, which is 143300.0% up from last year.
  • Supernus Pharmaceuticals' EBT Margin amounted to 30.17% in Q3 2025, which was down 557500.0% from 10.07% recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' EBT Margin ranged from a high of 25.58% in Q3 2024 and a low of 30.17% during Q3 2025
  • Moreover, its 5-year median value for EBT Margin was 6.66% (2022), whereas its average is 6.37%.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' EBT Margin skyrocketed by 282600bps in 2024, and later tumbled by -557500bps in 2025.
  • Supernus Pharmaceuticals' EBT Margin (Quarter) stood at 1.29% in 2021, then skyrocketed by 1529bps to 21.0% in 2022, then crashed by -97bps to 0.6% in 2023, then soared by 2414bps to 15.15% in 2024, then crashed by -299bps to 30.17% in 2025.
  • Its EBT Margin stands at 30.17% for Q3 2025, versus 10.07% for Q2 2025 and 3.89% for Q1 2025.